These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Oct 26, 2015The investment agreements include a private placement to investors at NIS 1.05 per share, for a total of approx. NIS 3.3 million. In addition, the investors signed agreements for the exercise of options granted in the context of the Dekel transaction, for approx. NIS 2.3 million.
Therapix, a company engaged in the development of cannabinoid-based drugs, announces today that it had entered into a series of investment agreements for a total of approx. NIS 5.6 million. The...
Aug 16, 2015
The Company wishes to update, in respect of the Company’s investment agreement in LaraPharm Ltd., that further to discussions recently held between the Company and LaraPharm’s management, the...
Aug 15, 2015Therapix signs an exclusive licensing agreement with Dekel regarding the "entourage effect" technologyThe Company and Dekel Pharmaceuticals Ltd. ("Dekel") have signed a definitive exclusive royalty baring license agreement regarding Dekel's technology, IPs and knowhow. The Company granted Dekel an option for investing in the Company at predefined terms. The agreement was approved by the ISA and TASE.
The Entourage Effect Cannabinoids are a diverse group of chemical compounds that operate on specific receptors in the body (CB1 and CB2). This family includes molecules that are derived from the...
Aug 4, 2015Therapix Biosciences to examine the development of a cannabinoidbased drug for treating Tourette's syndromeIn the last several decades, no new drug was developed or launched for treating Tourette's syndrome. Tourette's syndrome is a neurological disorder characterized by involuntary movements and vocalizations.
Further to Therapix Biosciences’ strategic plan determined at the beginning of 2014, the Company announced to investors this morning that the Company’s Board of Directors has decided to focus...
Jun 28, 2015Therapix to develop a cannabinoid-based drug for treating impairments in cognitive functioning and preventing Alzheimer’s disease based on research conducted at Tel Aviv UniversityEntered into an MOU with the University’s tech-transfer company, whereby it shall fund a research project for developing and adapting a technology related to low dosages of THC for treating cognitive functioning impairments.
Therapix Biosciences announces that it has entered into a non-binding memorandum of understandings with Ramot, Tel Aviv University’s technology transfer company, whereby the Company shall fund a...